logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12258417 B1

PDFFull Text
Date of Patent:
Mar. 25, 2025

Filed:

Aug. 29, 2017

Adenovirus armed with bispecific t cell engager

Applicant:

Akamis Bio Limited, Abingdon, GB;

Inventors:

Brian Robert Champion, Abingdon, GB;

Alice Claire Noel Bromley, Abingdon, GB;

Joshua David Freedman, Chigwell, GB;

Kerry David Fisher, Witney, GB;

Leonard William Seymour, Wootton by Woodstock, GB;

Assignee:

AKAMIS BIO LIMITED, Oxfordshire, GB;

Attorneys:

Dechert LLP

Andrew T. Wilkins

David M. Lee

Primary Examiner:

Hong Sang

Int. Cl.
CPC ...
C07K 16/30 (2006.01); A61K 35/761 (2015.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 14/52 (2006.01); C07K 16/28 (2006.01); C07K 16/40 (2006.01); C12N 15/86 (2006.01); C12N 15/861 (2006.01); A61K 35/768 (2015.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/30 (2013.01); A61K 35/761 (2013.01); A61K 39/39558 (2013.01); A61P 35/00 (2018.01); C07K 14/521 (2013.01); C07K 16/2809 (2013.01); C07K 16/40 (2013.01); C12N 15/86 (2013.01); C12N 15/861 (2013.01); A61K 35/768 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/585 (2013.01); A61K 2300/00 (2013.01); C07K 2317/31 (2013.01); C07K 2317/56 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/75 (2013.01); C07K 2319/92 (2013.01); C12N 2710/10332 (2013.01); C12N 2710/10343 (2013.01); C12N 2830/60 (2013.01); C12N 2840/44 (2013.01);
Abstract

A modified adenovirus, in particular Enadenotucirev (EnAd), armed with at least two bispecific T cell engagers each comprising at least two binding domains, wherein at least one of the domains is specific for a surface antigen on an immune cell of interest, such as a T-cell of interest. Also provided are a composition, such as a pharmaceutical formulation comprising the virus, use of the virus and virus formulations for treatment, such as in the treatment of cancer. The disclosure also extends to processes for preparing the virus.

Find Patent Forward Citations

Loading…